Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

By sjmartinez • December 13, 2024

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2024 Dec 9:S2352-3018(24)00247-9. doi: 10.1016/S2352-3018(24)00247-9. Epub ahead of print. PMID: 39667379.

Tags: Infectious Diseases, Publications

SPHERES: innovative registry addressing the new era of neuromyelitis optica spectrum disorders (NMOSD) therapy

Bennett JL, Middaugh N, Yeaman MR, Smith TJ, Behne MK, Crabtree M, McLean RR, Pappas DA, Levy M. SPHERES: innovative registry addressing the new era[...]

A pilot intervention to improve the management of urinary tract infections in outpatient settings

Madaras-Kelly KJ, Nakasone T, Maghari S, Taylor J, Nevers M, Crook J, Brintz B, Braunfeld JB, Goetz MB, Samore M. A pilot intervention to improve[...]

Phylodynamic analysis reveals disparate transmission dynamics of Mycobacterium tuberculosis complex lineages in Botswana

Wang Q, Barilar I, Minin VM, Modongo C, Moonan PK, Finlay A, Boyd R, Oeltmann JE, Molefi TL, Zetola NM, Brewer TF, Niemann S, Shin[...]